and Tauopathies


“Alzheimer & Tauopathies” Tean  belongs to the “Lille Neuroscience & Cognition” and is located Lille, France.

Our team is interested in pathophysiological mechanisms leading to dementia and is composed of 16 permanent researchers: full time research scientists, professors and associate professors and clinicians. We also welcome postdoctoral fellows and MSc/PhD students. Our work focuses on Tau, protein involved in the physiopathology of Alzheimer’s disease and related disorders referred to as Tauopathies, going from the gene to the clinic and from basic research to biomedical application.

“Alzheimer & Tauopathies” team is interested in molecular and pathophysiological mechanisms of Tau pathophysiology. Our main contribution has been on the characterization of neurodegenerative disorders with dysfunction in Tau metabolism (expression, splicing, etc.) and the development of experimental models. We also demonstrated that Tau proteins are biomarkers of these disorders and correlated to neuronal death.

Our current research should lead to new diagnostic and therapeutic strategies of Alzheimer’s disease and related disorders. To the level of the etiopathogenesis of Alzheimer’s disease, the understanding of the relationships between amyloid pathology and Tau pathology is our main goal. Any molecular actors potentially involved in one of these pathways are evaluated in our experimental “humanized” models, as well as the related pharmacological aspects.


Marine Denéchaud

Award of the prestigious i-PhD innovation competition

Drinking two to three cups of coffee a day would have virtues for the memory and the heart.

Coffee drinkers may be at lower risk of premature death

Steinert’s disease is caused by the abnormal repetitions of a small DNA sequence in the DMPK gene.
© Unsplash


Anti-pTau labeling of neurofibrillary degeneration in the hippocampus in a patient with Alzheimer’s disease.



Alzheimer’s disease: the challenges of research deciphered by 3 researchers supported by the FRM



Luc Buée, PhD.

CNRS research professor.
Head of the “Alzheimer & Tauopathies” team.
Director of the Lille Neuroscience & Cognition Research Center.
University of Lille, Faculty of Medicine.
Research :
Alzheimer & Tauopathies.

David Blum.
Inserm Research Professor.

Adjunct Professeur Taipei Medical University(Taïwan).
University of Lille, Faculty of Medicine.
Research :
Cerebral Homeostasis, Adenosine and its receptors, Metabolism, insulin resistance, neuroinflammation.
Methods: Animal models, behaviour, confocal microscopy, transcriptomics.

Marie-Christine Galas, PhD.
CNRS Research Professor.

University of Lille, School of Medicine.
Research: Nuclear tau, tau and genome integrity, tau and epigenomics.

Nicolas Sergeant, PhD.
Inserm research professor.

University of Lille, Faculty of Medicine
Research :
Pathophysiology of Tauopathies, biomarkers & new therapeutic targets.

Associate Professors/Professors – University-Associated

Dr. Valérie Buée-Scherrer, PhD.
Associate Professor (HDR-Docent)
University Artois, School of Sciences, Lens, France.
Teaching: Cell Biology.
Research : Molecular characterization of brain lesions found in neurodegenerat disorders. Studies in human and aivenimal models.
Methods: Biochemistry, Cell biology,  Molecular Biology, Immunohistochemistry.
Dr. Morvane Colin, PhD.
Associate Professor (HDR-Docent)
University of Lille, Faculty of Medicine.
Teaching: Cell Biology, Gene therapy & vectorology.
Research: “Tau spreading” Cell to cell transfer process; immunotherapy anti-tau, neuronal network.
Dedicated tools: Viral vectors, primary cultures, microfluidic, MEA, rodent model, animal models & intracranial delivery.
Dr. Sophie Halliez, PhD.
Associate Professor – Chair of excellence Inserm.
University of Lille, Faculty of Medicine.
Teaching : Molecular and cell neurobiology.
Research : Experimental models, physiological et pathological neural networks, cell mechanisms in tauopathies.
Methods :  Multielectrode arrays, microfluidics and neurobiology
Dr. Malika Hamdane, PhD.
Professor of Cell Biology (HDR-Docent).
University of Lille, Faculty of Medicine.
Teaching: Cell Biology, Biochemistry, Neuroscience.
Research: “Truncated Tau species”. The role in Alzheimer’s Disease and therapeutic and diagnosis applications.
Dr. Bruno Lefebvre, PhD.
Associate Professor (HDR).
University of Lille, Faculty of Medicine.
Teaching: Biochemistry, molecular and cell biology, epigenetics.
Research: Tau and nucleic acids.

Dr. Didier Vieau, PhD.
Professor of Physiology.
University of Lille, Faculty of “Sciences et Technologies”.
Teaching: Physiology and endocrinology.
Research : Short- and long-term influences of the perinatal environment on the programming of the stress response and chronic adult diseases such as obesity, diabetes and Alzheimer disease.

Associate Professors and Professors
University & Hospital-Associated

Prof. Vincent Deramecourt, MD, PhD.
professor of histology – Hospital Biologist.
University of Lille, Faculty of Medicine.
Teaching: : Anatomo-pathology, Histology, Dean's Assessor for PACES.
Research : Biomarkers of dementias - Clinical correlation.
Hospital activities: Neurologist - Neuropathologist.
Dr. Claire-Marie Dhaenens, PharmD, PhD, HDR, MCU-PH
University of Lille, Faculty of Medicine.
Research : Involved in genetics and epigenomics of Tauopathies and neurodegenerative disorders. Investigation of the MAPT gene regulation (alternative splicing, alternative promoter usage, transcription…) to explain the differential expression of Tau proteins in human brain and in experimental models.
Dr. Thibaud Lebouvier, MD, PhD.
Associate Professor – Hospital Biologist.
University of Lille, Faculty of Medicine.
Research : Frontotemporal lobar degenerations.
Hospital duties:  Neurologist.
Prof. Bernard Sablonnière, MD, PhD.
Professor, Hospital Biologist.
University of Lille, Faculty of Medicine.
Teaching: Biochemistry and molecular biology.
Research: Epigenomics, spino-cerebellar ataxia.
Hospital duties: Neurobiology, genetic diagnosis, biomarkers of dementia.
Dr Susanna Schraen-Maschke, PharmD, PhD, HDR, MCU-PH
University of Lille, Faculty of Medicine.
Research: Involved in the translational development and evaluation of biomarkers of Alzheimer’s disease in human biological fluids. Samples come from french national cohorts of patients, and on samples of the Lille University Hospital care. The aim is to evaluate their interest for diagnosis and prognosis of dementia.
Hospital duties : Biochemistry and Biomarkers of Dementias.
Dr Vincent Huin, MD, PhD, MCU-PH
University of Lille, Faculty of Medicine.
Research : Epigénomique des maladies neurodégénératives. Maladies à expansions de triplets
Hospital duties : Biochemistry and Genetics of Neurodegenerative Diseases.
Dr Marie Dubar, M.D, Ph.D, MCU-PH
Université de Lille, Faculté de Médecine.

Research support staff

 Séverine Bégard
Inserm engineer
 Thomas Bouillet
Ingénieur d'Etude, CDD
 Anaïs Poncet
Ingénieure Hospitalière, CDD
 Emilie Faivre
University of Lille engineer
 Raphaëlle Caillierez
University of Lille engineer
 Sébastien Carrier
University of Lille technician
 Sabiha Eddarkaoui
University of Lille engineer
 Thomas Comptdaer
University of Lille technician

Post Doctoral Researchers

 Sayed Rassul Muhammed, PhD
 Guedjdal Sarah

Doctoral students

 Pinheiro Werner
 Denechaud Marine
 Coku Ilda
 Kraiem Sarra
 Montmasson Claire
 Gauvrit Thibaut
 Benderradji Hamza


  • PERBET Romain, PhD
  • TAUTOU Marie, PhD
  • LEROUX Elodie, PhD
  • RICO Thomas, PhD
  • SOUZA Cristiano, PhD
  • LEROY Mélanie, PhD
  • ZEJNELI Orgeta, PhD
  • BAUD Catherine, PhD
  • CARVALHO Kevin, PhD
  • GOMEZ-MURCIA Victoria, PhD
  • MERIAUX Céline, PhD
  • SCHIRMER Claire, PhD
  • VINDTDEUX Valérie, PhD
  • ALBERT Marie, PhD
  • DANIS Clément, PhD
  • ERDUAL Edmone, PhD
  • EVRARD Caroline, PhD
  • GILLES, Mélissa, PhD
  • HOMA Mégane, PhD
  • ALVES-PIRES Claire, PhD
  • ANDO Kunie, PhD
  • BELARBI Karim, PhD
  • BOMBOIS Stéphanie, MD, PhD
  • BROUILLETTE Jonathan, PhD
  • BURNOUF Sylvie, PhD
  • BUSSIERE Thierry, PhD
  • CAILLET-BOUDIN Marie-Laure, PhD
  • CARPENTIER Céline, PhD
  • CELLAI Lucrezia, PhD
  • CHARTIER-HARLIN Marie-Christine, PhD
  • DAVID Jean-Philippe, MD, PhD
  • DELAY Charlotte, PhD
  • DELOBEL Patrice, PhD
  • DELPLANQUE Jérôme, PhD
  • DERISBOURG Maxime, PhD
  • DOURLEN Pierre, PhD
  • DUJARDIN Simon, PhD
  • FERNANDEZ-GOMEZ Francisco J, PhD
  • FERREIRA Stéphanie, PhD
  • FERRETTI Roberta, PhD
  • FLAMENT Stéphane, PhD
  • GELE Patrick, PhD
  • GOMPEL Marie, PhD
  • HUIN Vincent , MD, PhD
  • HUMEZ Sandrine, PhD
  • JUMEAU Fanny, PhD
  • LAMBERT Jean-Charles, PhD
  • LAURENT Cyril, PhD
  • LEBOUCHER Antoine, PhD
  • LECOLLE Katia, PhD
  • LEFRANC Didier, PhD
  • LE FRECHE Hélène, MD
  • LEGHAY Coline, PhD
  • LEROY Olivier, PhD
  • MAILLIOT Christel, PhD
  • MARCINIAK Élodie, PhD
  • MARINANGELI Claudia, PhD
  • MAURAGE Claude-Alain, MD, PhD
  • PAPEGAEY Anthony, PhD
  • PEREZ-TUR Jordi, PhD
  • PERMANNE Bruno, PhD
  • SAMBO Anne-Véronique, PhD
  • SAUTIERE Pierre-Éric, PhD
  • SCHINDOWSKI Katharina, PhD
  • SIGALA Julien, MD, PhD
  • SOULIE Cathia, PhD
  • SPOLCOVA Andrea, PhD
  • SULTAN Audrey, PhD
  • TRAN Hélène, PhD
  • TROQUIER Lætitia, PhD
  • VERMERSCH Patrick, MD, PhD
  • VIOLET Marie, PhD
Our project has the following scheme: A. MAPT regulation: epigenomics, transcriptional and post-transcriptional B. New insights on Tau functions C. Modulating Tau pathology D. Translational research: diagnostic and therapeutic applications  

A. MAPT regulation: epigenomics, transcriptional and post-transcriptional

The human Tau / MAPT gene is unique and contains 16 exons located on more than 150 kb on the long arm of chromosome 17 (17q21). The Tau primary transcript contains 16 exons. In the human brain, exon -1 is transcribed but not translated. Exons 1, 4, 5, 7, 9, 11, 12, 13 and 14 are constituent exons. Exons 2, 3 and 10 are spliced ​​alternately and are specific to the adult brain. Thus, in the human brain, the alternative splicing of these three exons makes it possible to obtain six mRNAs (2-3-10-, 2 + 3-10-, 2 + 3 + 10-, 2-3-10 +; 2 + 3- 10+, 2 + 3 + 10 +) leading to the expression of 6 protein isoforms (3R (10-) and 4R (10+)). A growing body of literature suggests that change in alternative expression or splicing may contribute to Tau-related neurodegeneration. Thus, modification of the expression and / or splicing of MAPT leads to frontotemporal dementia but can also be observed in other Tauopathies including Alzheimer’s disease and myotonic dystrophy, CUG triplet expansion disease. It is therefore essential to understand the epigenomic, the transcriptional and post-transcriptional regulation of the MAPT gene.

B. New insights on Tau functions

Tau protein is originally defined as a microtubule-associated protein. Tau is also a signaling protein that clearly has other functions in the neuron and neuronal networks via membrane, nuclear and extracellular processes. These new functions can be carried by specific protein domains and / or post-translational modifications (phosphorylation, acetylation, proteolysis, etc.).

 In this context, the laboratory is interested in (1) the role of Tau in the nucleus in particular in the protection of nucleic acids, the structure of chromatin and transcription; (2) the role of new amino-truncated forms of Tau in neuronal signaling and physiopathological development, particularly in patients; (3) the role of Tau as an extracellular signaling factor with the aim of understanding the mechanisms leading to its secretion under physiological and pathological conditions; (4) the role of Tau as a regulator of neuronal signaling.

C. Modulating Tau pathology

The laboratory is interested rôle pathogénique des différentes espèces moléculaire in the pathogenic role of the different molecular species of Tau especially in the prion-like spreading hypothesis. We are also interested in the role of extrinsic factors in the toxicity of these species with an interest for APP and the Tau-Aß interface, the role of potential pathological modulators resulting from proteomic / transcriptomic / genomic analyzes (GWAS with LabEx DISTALZ ), environmental factors (including caffeine and its targets, A2A adenosinergic receptors) and cellular factors (neurons vs. glial cells).

D. Translational research: diagnostic and therapeutic applications

Our laboratory is committed to developing recherche translationnelle en interface avec les biologistes et clinicientranslational research in interface with biologists and clinicians. On one hand, we are interested in the identification of markers in autopsy-derived brain specimens and also body fluids (cerebrospinal fluid, blood…), allowing the differential diagnosis of dementia. We are developing a small cohort ECTAUSOME for a proof of concept. The emergence of new predictive biomarkers is essential for therapeutic implementation. On the other hand, we are developing preclinical research aimed at defining new therapeutic strategies. As such, we are exploring new anti-Tau compounds either by small molecule approaches (anti-aggregating, targeting protein chaperones…) in collaboration with the team of Patricia Melnyk – or immunotherapeutic approaches. The adenosinergic receptor pathway is also explored. These approaches are conducted in partnership with industry. It is notable that one of our molecules (MSBD) has led to the development of a company (AlzProtect) and a clinical trial. This molecule should move into phase 2 soon.

In conclusion, the strength of our laboratory welcoming researchers (biochemists, cell and molecular biologists, neurobiologists) and clinicians is to integrate fundamental, pre-clinical and clinical approaches to better understand the biology of Tau, its physiopathological role and the impact in terms of diagnosis and therapy.

• Publications
PhD Theses




Arandel L, Matloka M, Klein AF, Sureau A, Ney M, Rau F, Cordier A, Kondili M, Polay-Espinoza M, Naouar N, Ferry A, Lemaitre M, Begard S, Colin M, Lamarre C, Tran H, Buée L, Marie J, Sergeant N*, Furling D* (2022) Decoy gene therapy based on engineered expanded-repeat binding protein prevents RNA toxicity in Myotonic Dystrophy. Nature Biomedical Engineering, (in press)

Benderradji H, Kraiem S, Courty E, Eddarkaoui S, Bourouh C, Faivre E, Rolland L, Caron E, Besegher M, Oger F, Boschetti T, Carvalho K, Thiroux B, Gauvrit T, Nicolas E, Gomez-Murcia V, Bogdanova A, Bongiovanni A, Muhr-Tailleux A, Lancel S, Bantubungi K, Sergeant N, Annicotte JS, Buée L, Vieau D, Blum D, Buée-Scherrer V (2022) Impaired glucose homeostasis in a tau knock-in mouse model. Front Mol Neurosci, (in press)

Danis C*, Dupré E*, Zejneli O*, Caillierez R, Arrial A, Bégard S, Mortelecque J, Eddarkaoui S, Loyens A, Cantrelle FX, Hanoulle X, Rain JC, Colin M, Buee L*, Landrieu I* (2022) Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther, (in press)

Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant A, Tréluyer JM, Abdoul H, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G , Volpe-Gillot L, Paccalin M, Robert PH, Godefroy O, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A on behalf of the BALTAZAR study group. Plasma β-amyloid (Aβ) as a relevant prognosis biomarker for conversion to dementia in subjects with mild cognitive impairment. The BALTAZAR Alzheimers Dement, (In press)

Leroux E, Perbet R, Caillierez R, Richetin K, Lieger S, Espourteille J, Bouillet T, Begard S, Danis C, Loyens A, Toni N, Deglon N, Deramecourt V, Schraen-Maschke S, Buee L*, Colin M* (2022) Extracellular vesicles: major actors of heterogeneity in tau spreading among human tauopathies. Mol Ther, (in press)

Sexton C, Snyder H, Beher D, Boxer AL, Brannelly P, Brion JP, Buée L, Cacace AM, Chételat G, Citron M, DeVos SL, Diaz K, Feldman HH, Frost B, Goate AM, Gold M, Hyman BT, Johnson K, Karch CM, Kerwin DR, Koroshetz WJ, Litvan I, Morris HR, Mummery CJ, Mutamba J, Patterson MC, Quiroz YT, Rabinovici GD, Rommel A, Shulman MB, Toledo-Sherman LM, Weninger S, Wildsmith KR, Worley SL, Carrillo MC. Current directions in tau research: Highlights from Tau 2020. Alzheimers Dement, 2021, 1-20.

Vieau D, Gauvrit T, Benderradji H, Buee L, Blum D (2022) Early-life environment influence early-onset Alzheimer’s disease. Cell Dev. Biol. - Epigenomics and Epigenetics, (in press).



Blum D, Lopes LV (2021) Stabilizing synapses. Science 374(6568):684-685. doi: 10.1126/science.abm3902

Brigas HC, Ribeiro M, Coelho JE, Gomes R, Gomez V, Carvalho K, Faivre E, Pereira S, Darrigues J, Antunes de Almeida A, Buée L, Dunot J, Marie H, Pousinha PA, Blum D, Silva-Santos B, Lopes LV, Ribot JC. IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. Cell Reports, 36(9):109574

Carvalho K, Martin E, Cès A, Sarrazin N, Youssef I, Lagouge-Roussey P, Prigent A, Boluda S, Huin V, Fontaine B, Buée L, Delatour B, Dutar P, Sennlaub F, Guillonneau X, Blum D, Delarasse C. P2X7-deficiency rescues plasticity and cognitive deficits in a mouse model of Tauopathy. Prog Neurobiol, 206:102139

Chang CP, Chang YG, Chuang PY; Thi Ngoc Nguyen A; Wu KC, Chou FY; Cheng SJ, Chen HM, Jin LW, Carvalho K, Huin V, Buée L, Liao YF, Lin CJ, Blum D, Chern Y. ENT1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathol Commun 9(1) 112

Damotte V, van der Lee SJ, Chouraki V, Grenier-Boley B, Simino J, Adams  H, Tosto  G, White  C, Terzikhan  N, Cruchaga  C, Knol  MJ, Li  S, Schraen S, Grove ML, Satizabal  C, Amin  N, Berr  C, Younkin S, Alzheimer’s Disease Neuroimaging Initiative, Gottesman RF, Buée L, Beiser  A, Knopman  DS, Uitterlinden A, DeCarli C, Bressler J, DeStefano A, Dartigues JF, Yang Q, Boerwinkle E, Tzourio C, Fornage M, Ikram MA, Amouyel P, de Jager P, Reitz C, Mosley Jr TH, Lambert JC, Seshadri S, Van Duijn C (2021) Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants. Alzheimers Dement, 17(10):1663-1674

Hartnell IJ, Blum D, Nicoll JAR, Dorothee G, Boche D (2021) Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain. 144(3):724-745. doi: 10.1093/brain/awaa457. PMID: 33527991.

Lam S, Petit F, Hérard AS, Boluda S, Eddarkaoui S, Guillermier M, The Brainbank Neuro-CEB Neuropathology Network, Buée L, Duyckaerts C, Haïk S, Picq JL, Dhenain M (2021) Amyloid and tau pathologies, cognitive impairments and cerebral atrophy after Alzheimer brain extracts inoculation in a primate. Acta Neuropathol Commun, 9(1):165. 

Lantoine J, Procès A, Villers A, Halliez S, Buée L, Ris L, Gabriele S (2021) Inflammatory molecules released by mechanically injured astrocytes trigger pre-synaptic loss in cortical neuronal networks. ACS Chem Neurosci, 12(20):3885-3897

Leroy M, Bertoux M, Skrobala E, Mode E, Adnet-Bonte C, Le Ber I, Bombois S, Cassagnaud P, Chen Y, Deramecourt V, Lebert F, Mackowiak MA, Sillaire AR, Wathelet M, Pasquier F, Lebouvier T; Méotis network (2021) Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimers Res Ther. 13(1):19. doi: 10.1186/s13195-020-00753-9.

Maté de Gérando A, d'Orange M, Augustin E, Joséphine C, Aurégan G, Gaudin-Guérif M, Guillermier M, Hérard AS, Stimmer L, Petit F, Gipchtein P, Jan C, Escartin C, Selingue E, Carvalho K, Blum D, Brouillet E, Hantraye P, Gaillard MC, Bonvento G, Bemelmans AP, Cambon K (2021) Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. Brain. 144(4):1167-1182. doi: 10.1093/brain/awab011.

Nebie O, Carvalho K, Barro L, Delila L, Faivre E, Renn TY, Chou ML, Wu YW, Nyem-Erdene A, Chou SY, Buée L, Hu CJ, Peng CW, Devos D, Blum D, Burnouf T (2021) Human platelet secretome brain administration for traumatic brain injury: pre-clinical assessment. Brain, 144(10) 3142-58.

Nebie O, Barro L, Wu YW, Knutson F, Buée L, Devos D, Peng CW, Blum D, Burnouf T (2021) Heat-treated human platelet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. Platelets, 32(2): 226-37. doi: 10.1080/09537104.2020.1732324

Nyam-Erdene A, Nebie O, Delila L, Buée L, Devos D, Chou SY, Blum D, Burnouf T (2021) Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. ACS Biomater Sci Eng, 7(12): 5823-5835. doi: 10.1021/acsbiomaterials.1c01226.

Pietrowski MJ, Gabr AA, Kozlov S, Blum D, Halle A, Carvalho K (2021) Glial Purinergic Signaling in Neurodegeneration. Front Neurol. 12:654850. doi: 10.3389/fneur.2021.654850.

Rico T, Gilles M, Chauderlier A, Comptdaer T, Magnez R, Chwastyniak M, Drobecq H, Pinet F, Thuru X, Buee L, Galas MC, Lefebvre B (2021) Tau stabilizes chromatib compaction. Cell Dev. Biol - Cellular Biochemistry, 9:740550

Susloparova A, Halliez S, Begard S, Colin M, Buée L, Pecqueur S, Alibart F, Thomy V, Arscott S, Pallecchi E, Coffinier Y (2021) Low impedance and highly transparent microelectrode arrays (MEA) for in vitro neuron electrical activity probing. Sens Actuators B Chem, 327:128895

Tautou M, Eddarkaoui S, Descamps F, Larchanché PE, El Bakali J, Goveas LM, Dumoulin M, Lamarre C, Blum D, Buee L, Melnyk P, Sergeant N (2021) A β‐secretase modulator decreases Tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration. Front Pharmacol, 12:679335.

Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, Kinoshita PF, Cazareth J, Badot C, Fragaki K Bussiere R, Martin C, Mary R, Bauer C, Pagnotta S, Paquis-Flucklinger V, Buée-Scherrer V, Buée L, Lacas-Gervais S, Checler F, Chami M (2021) Amyloid precursor protein C-terminal fragments accumulation triggers mitochondrial structure, function and mitophagy defects in Alzheimer’s disease models and human brains. Acta Neuropathol, 141(1): 39-65.

Vautheny A, Duwat C, Auregan G, Joséphine C, Hérard AS, Jan C, Mitja J, Gipchtein P, Gaillard MC, Buée L, Blum D, Hantraye P, Bonvento G, Brouillet E, Cambon K, Bemelmans AP (2021) THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. Neurobiol Dis, 155:105398. doi: 10.1016/j.nbd.2021.105398.

Wang ZH, Xia Y, Wu Z, Kang SS, Zhang JC, Liu P, Liu X, Song W, Huin V, Dhaenens CM, Yu SP, Wang XC, Ye K (2021) Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer's disease pathology in a mouse model. Prog Neurobiol. 209:102212. doi: 10.1016/j.pneurobio.2021.102212.



Ando K, De Decker R, Vergara C, Yilmaz Z, Mansour S, Suain V, Sleegers K, de Fisenne MA, Houben S, Potier MC, Duyckaerts C, Watanabe T, Buée L, Leroy K, Brion JP (2020) Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathol, 139:773–89 doi:10.1007/s00401-020-02125-x

Ahmed T, Van Der Jeugd A, Caillierez R, Buee L, Blum D, D'Hooge R, Balschun D (2020) Chronic sodium selenate treatment restores deficits in cognition and synaptic plasticity in a murine model of tauopathy. Front Mol Neurosci, 13:570223. doi: 10.3389/fnmol.2020.570223

Bourefis AR, Campanari ML, Buee-Scherrer V, Kabashi E. Functional characterization of a FUS mutant zebrafish line as a novel genetic model for ALS. Neurobiol Dis. 142:104935. doi: 10.1016/j.nbd.2020.104935.

Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, Buée L (2020) Exploring anti-tau immunotherapy within the hypothesis of the prion-like propagation. Acta Neuropathol, 139: 3-25

Degiorgis L, Karatas M, Sourty M, Faivre E, Lamy J, Noblet V, Bienert T, Reisert M, von Elverfeldt D, Buée L, Blum D, Boutillier AL, Armspach JP, Blanc F, Harsan LA (2020) Remodeling of cerebral networks architecture anticipate behavioral deficits in a tauopathy mouse model of Alzheimer's disease. Brain, 143(12):3748-3762. doi: 10.1093/brain/awaa312.

Duriez P, Eddarkaoui S, Blum D, Dickson SL, Gorwood P, Tolle V, Viltart O (2020) Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice? Horm Behav. 124:104807. doi: 10.1016/j.yhbeh.2020.104807.

Gomez-Murcia V, Sandau U, Ferry B, Parrot S, Laurent C, Basquin M,  Buée L, Boison D, Blum D (2020) Hyperexcitability and seizures in the THY-Tau22 mouse model of Tauopathy. Neurobiol Aging, 94: 265-270.

Hector A, McAnulty C, Piché-Lemieux ME, Alves-Pires C, Buée-Scherrer V, Buée L*, Brouillette J* (2020) Tau hyperphosphorylation induced by the anesthetic agent ketamine- xylazine involved the calmodulin-dependent protein kinase II. FASEB J, 34(2):2968–77

Homa M, Loyens A, Eddarkaoui S, Faivre E, Deramecourt V, Maurage CA, Buée L, Huin V, Sablonnière B (2020) The TMEM240 Protein, Mutated in SCA21, Is Expressed in Purkinje Cells and Synaptic T Cerebellum 19(3):358‐369. doi:10.1007/s12311-020-01112-y

Richetin K, Steullet P, Pachoud M, Perbet R, Parietti E, Maheswaran M, Eddarkaoui S, Bégard S, Pythoud C, Rey M, Caillierez R, Do KQ, Halliez S, Bezzi P, Buee L, Leuba G, Colin M, Toni N, Déglon N (2020) Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer’s disease. Nature Neurosci, 23(12): 1567-79.

Runhart EH, Khan M, Cornelis SS, Roosing S, Del Pozo-Valero M, Lamey TM, Liskova P, Roberts L, Stöhr H, Klaver CCW, Hoyng CB, Cremers FPM, Dhaenens CM; Disease Consortium Study Group (2020) Association of Sex With Frequent and Mild ABCA4 Alleles in Stargardt Disease. JAMA Ophthalmol. 138(10):1035-1042. doi: 10.1001/jamaophthalmol.2020.2990.

Sierksma A, Lu A, Salta E, Mancuso R, Zoco J, Blum D, Buée L, De Strooper B, Fiers M (2020) Novel Alzheimer risk genes determine the microglia response to amyloid ß but not to TAU pathology. EMBO Mol Med, 12(3): e10606.

Temido-Ferreira M, Ferreira DG, Batalha VL, Marques-Morgado I, Coelho JE, Pereira P, Gomes R, Carvalho S, Canas PM, Cuvelier L, Buée-Scherrer V, Faivre E, CE, Pimentel J, Schiffmann SN, Buée L, Outeiro TF, Bader M, Blum D, Cunha RA, Marie H, Pousinha PA, Lopes LV (2020) Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Mol Psychiatr, 25(8):1876-1900

Verelst J, Geukens N, Eddarkaoui S, Vliegen D, De Smidt E, Rosseels J, Franssens V, Molenberghs S, Francois C, Stoops E, Bjerke M, Engelborghs S, Laghmouchi M, Carmans S, Buée L, Vanmechelen E, Winderickx J, Thomas D (2020) A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. Front Mol Biosci, 7:48. doi:10.3389/fmolb.2020.00048

Zheng J, Akbari M, Schirmer C, Reynaert ML, Loyens A, Lefebvre B, Buée L, Croteau DL, Galas MC, Bohr VA (2020) Hippocampal tau oligomerization early in tau pathology coincides with a transient alteration of mitochondrial homeostasis and DNA repair in a mouse model of tauopathy. Acta Neuropathol Commun, 8(1):25. doi:10.1186/s40478-020-00896-8



Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M, Citron M, Downey P, Courade JP, Buée L*, Colin M* (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain, 142(6): 1736-1750

Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, Temido-Ferreira M, Coelho JE, Mériaux C, Eddarkaoui S, Le Gras S, Dumoulin M Cellai L, NeuroCEB Brain Bank, Landrieu I, Chern Y, Hamdane M, Buée L, Boutillier AL, Levi S, Halle A, Lopes LV, Blum D (2019) Exacerbation of C1q dysregulation, synaptic loss and memory deficits in Tau pathology linked to neuronal adenosine A2A receptors. Brain, 142(11): 3636-54

Corvol JC, Buée L (2019) A new step towards targeting tau. Lancet Neurol, 18:517-8.

Domise M, Sauvé F, Didier S, Caillerez R, Bégard S, Carrier S, Colin M, Marinangeli C, Buee L, Vingtdeux V (2019) Neuronal AMP-activated protein kinase (AMPK) hyper-activation induces synaptic loss by an autophagy mediated process. Cell Death Dis, 10:221

Dupré E, Danis C, Arrial A, Cantrelle FX, Merzougui H, Hanoulle X, Colin M, Rain JC, Buée L*, Landrieu I* (2019) Single chain antibody fragments as new tools for studying the neuronal Tau protein physiopathology. ACS Chemical Neurosci, 10(9):3997-4006

Faldini E, Ahmed T, Buee L, Blum D, Balschun D (2019) Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models. Acta Neuropathol Comm, 7:202

Fichou Y, Al-Hilaly YK, François Devred F, Smet-Nocca C Tsvetkov PO, Verelst J, Winderickx J, Geukens N, Vanmechelen E, Perrotin A, Serpell L, Hanseeuw B, Medina M, Buée L*, Landrieu I* (2019) The elusive Tau Molecular structures: Can we translate the recent breakthroughs into new targets for intervention? Acta Neuropathol Commun, 7:31

Gary C, Lam S, Herard AS, Koch JE, Petit F, Gipchtein P, Sawiak SJ, Caillierez R, Eddarkaoui S, Colin M, Aujard F, Deslys JP, French neuropathology network, Brouillet E, Buée L, Comoy EE, Pifferi F, Picq JL, Dhenain M (2019) Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. Acta Neuropathol Commun, 7(1)126.

Houben S, Leroy K, Ando K, Yilmaz Z, Widomski C, Buée L, Brion JP (2019) Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model. Neurobiol Dis, 127:131-141

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus R, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock D, Blum D, Latz E, Buee L, Heneka M (2019) NLRP3 inflammasome activation drives tau pathology. Nature, 575(7784): 669-673

Jadhav S, Avila J, Schöll M, Kovacs G, Kövari E, Skrabana R, Evans L, Kontsekova E, Malawska B, de Silva R, Buée L*, Zilka N* (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun, 7: 22.

Leboucher A, Ahmed T, Caron E, Tailleux A, Raison S, Joly Amado A, Marciniak E, Carvalho K, Hamdane M, Bantubungi K, Lancel S, Eddarkaoui S, Caillierez R, Vallez E, Staels B, Vieau D, Balschun D, Buée L*, Blum D* (2019) Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiol Dis, 125 :14-22.

Lemaire Q, Raffo-Romero A, Arab T, Van Camp C, Drago F, Forte S, Gimeno JP, Begard S, Colin M, Vizioli J, Sautière PE, Salzet M, Lefebvre C (2019) Isolation of microglia-derived extracellular vesicles: towards miRNA signatures and neuroprotection. J Nanobiotechnology. 17(1):119. doi: 10.1186/s12951-019-0551-6.

Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte A, Giusti P, Zusso M, Robert P, Frisoni G, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B (2019) Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med, 286(4):398-437

Nebie O, Devos D, Vingtdeux V, Barro L, Devedjian JC, Jonneaux A, Chou ML, Bordet R, Buée L, Knutson F, Blum D, Burnouf T (2019) The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. J Biomed Sci, 26(1):89. doi: 10.1186/s12929-019-0579-9

Paiva I, Carvalho K, Cellai L, Santos P, Pavlou MAS, Jain G, Gnad T, Pfeifer A, Vieau D, Fischer A, Buée L, Outeiro TF, Blum D (2019) A2AR-induced transcriptional deregulation in astrocytes: an in vitro Glia, 67(12):2329-2342

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Le Fur N, Evrard C, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Hamdane M, Buee L, Melnyk P (2019) New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer’s disease. Neurobiol Dis, 129: 217-33.

Shrivastava AN, Redeker V, Pieri L, Bousset L, Renner M, Madiona K, Mailhes-Hamon C, Coens A, Buée L, Hantraye P, Triller A, Melki R (2019) Clustering of tau fibrils impairs the synaptic composition of a3-Na+/K+-ATPase and AMPA receptors. EMBO J, 38, e99871

Zappettini S, Faivre E, Ghestem A, Carrier S, Buée L, Blum D, Esclapez M, Bernard C (2019) Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. Front Cell Neurosci; 13: 438. doi: 10.3389/fncel.2019.00438.



  • EP17305355.4 Hamdane M, Derisbourg M, Leghay C, Chiappetta G, Verdier Y, Vinh J, Blum D, Buée L. New Tau species. March 28, 2017.

Patents accepted

  • WO2015068075  –  Buée L, Colin M, Hantraye P, Aron Badin R, Dujardin S, Bemelmans A, Brouillet E. DETECTION OF TAU.

Licenced Patents

  • US20160356785 Sergeant N, Mitchell V, Jumeau F, Sigala J. Methods for determining human sperm quality. Licence exclusive à 4BioDx.
  • WO2016146655 : Sergeant N, Melnyk P, Buée L. Novel 1,4-bis(3-aminopropyl)piperazine derivatives and its use. 16 mars 2015 (Accord de licence en discussion avec la société Alzprotect).
  • WO2015032842 : Sergeant N, Mitchell V, Jumeau F, Sigala J. Méthodes de détermination de la qualité du sperme humain. Licence exclusive à 4BioDx.
  • WO2014102339 : Barrier M, Buée L, Burlet S, Delacourte A, Estrella C, Melnyk P, Sergeant N, Verwaerde P. Sulfate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine. AlzProtecT – phase I terminée en 2015.
  • W02006051489 : Melnyk Patricia, Sergeant Nicolas, Buée Luc, Delacourte André, Inserm, Université de Lille II, « Use of 1, 4-bis(3 aminopropyl)piperazine derivatives in therapy ». Licensed to AlzProtecT.
    Molécule actuellement en essai clinique chez l’homme – phase I terminée en 2015.

Phd Theses

Ongoing Phd

  • CARVALHO Kevin (D2 en 2017 – thesis director : David BLUM)
  • DENECHAUD Marine (D1 en 2018 – thesis director : Marie-Christine GALAS)
  • ERDUAL Edmone (D3 en 2017 – thesis director : Christelle CAUFFIEZ et David BLUM)
  • GUEDJDAL Sarah (D1 en 2017 – thesis director : Malika HAMDANE)
  • GUIRAUD Sebastien (D3 en 2018 – thesis director : MC GALAS/R PARDOSSI)
  • HOMA Megane (D2 en 2017 – thesis director : Bernard SABLONNIERE)
  • NEBIE Ouada (D1 en 2017 – thesis director : David BLUM et Thierry BURNOUF)
  • LEROUX Elodie (D1 en 2018 – thesis director : Morvane COLIN)
  • LEROY Melanie (D1 en 2018 – thesis director : Vincent DERAMECOURT)
  • PERBET Romain (D1 en 2017 – thesis director : Morvane COLIN)
  • RICO Thomas (D1 en 2018 – thesis director : Bruno LEFEBVRE)
  • SOUSA Cristiano (D1 en 2018 – thesis director : Malika HAMDANE et Karen VANHOORELBEKE)
  • TAUTOU Marie (D1 en 2018 – thesis director : Nicolas SERGEANT)
  • ZEJNELI Orgeta (D1 en 2018 – thesis director : Luc BUEE et Isabelle LANDRIEU)

Theses defended since 2013

  • ALBERT Marie (sout. le 10/12/2018 directed by Morvane COLIN) (title/abstract)
  • DANIS Clément (soutenance le 14/12/2018 directed by Isabelle LANDRIEU et Luc BUEE) (title/abstract)
  • DOMISE Manon (soutenance le 17/12/2018 directed by Valerie VINGTDEUX) (title/abstract)
  • EVRARD Caroline (sout. le 20/11/2018 directed by Nicolas SERGEANT) (title/abstract)
  • GILLES Melissa (sout. le 13/11/2018 directed by Bruno LEFEBVRE) (title/abstract)
  • TARDIVEL-SAFI Meryem (sout. le 6/12/2017 directed by Morvane COLIN) (title/abstract)
  • LEGHAY Coline (sout. le 19/09/2017 directed by Malika HAMDANE (title/abstract)
  • PAPEGAEY Anthony (sout. le 19/12/2016) directed by Valerie BUEE-SCHERRER (title/abstract)
  • CHAUDERLIER Alban (sout. le 16/12/2016) directed by Marie-Christine GALAS (title/abstract)
  • HUIN Vincent (sout. le 15/12/2016) directed by Bernard SABLONNIERE et Claire-Marie DHAENENS (title/abstract)
  • SIGALA Julien (sout. le 08/12/2016) directed by Valérie MITCHELL et Nicolas SERGEANT (title/abstract)
  • MARCINIAK Elodie (sout. le 14/12/2015) directed by Sandrine HUMEZ (title/abstract)
  • ALVES-PIRES Claire (sout. le 10/12/2015) directed by Luc BUEE et Christelle MONACA-CHARLEY (title/abstract)
  • SPOLCOVA Andrea (sout. le 23/09/2015) directed by Marie-Christine GALAS (title/abstract)
  • DUJARDIN Simon (sout. le 21/09/2015) directed by Morvane COLIN (title/abstract)
  • DERISBOURG Maxime (sout. le 30/03/2015) directed by Malika HAMDANE (title/abstract)
  • VIOLET Marie (sout. le 28/02/2014) directed by Marie-Christine GALAS (title/abstract)
  • LAURENT Cyril (sout. le 17/12/2013) directed by David BLUM (title/abstract)
  • CARPENTIER Céline (sout. le 16/12/2013)directed by Marie-Laure CAILLET-BOUDIN (title/abstract)
  • WATTEZ Jean-sébastien (sout. le 09/12/2013) directed by Didier VIEAU et Benoit FOLIGNE (title/abstract)
  • JUMEAU Fanny (sout. le 16/09/2013) directed by Valérie MITCHELL et Nicolas SERGEANT (title/abstract)